Optimal extent of initial parathyroid resection in patients with multiple endocrine neoplasia syndrome type 1: A meta-analysis

نویسندگان

چکیده

Background Hyperparathyroidism is an almost universal feature of multiple endocrine neoplasia type 1 syndrome. We present a systematic review and meta-analysis the postoperative outcomes patients undergoing initial operative treatment primary hyperparathyroidism complicating 1. Methods A comprehensive literature search was performed with priori defined exclusion criteria for studies comparing total parathyroidectomy, subtotal less than parathyroidectomy. Results Twenty-one incorporating 1,131 (272 510 349 parathyroidectomy) were identified. Pooled results revealed increased risk long-term hypoparathyroidism in parathyroidectomy (relative 1.61; 95% confidence interval, 1.12?2.31; P = .009) versus those In or comparison group, greater recurrence 1.37; 1.05?1.79; .02), persistence 2.26; 1.49?3.41; .0001), reoperation 2.48; 1.65?3.73; < .0001) noted patients, albeit lesser 0.47; 0.29?0.75; .002). Conclusion Subtotal compares favorably to exhibiting similar rates decreased propensity hypoparathyroidism. The benefit negated by increase recurrence, persistence, reoperation. Future evaluating performance specific phenotypes should be pursued effort delineate patient-tailored, approach that optimizes outcomes.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Menin mutations in patients with multiple endocrine neoplasia type 1.

Multiple endocrine neoplasia type 1 (MEN-1) is a familial cancer syndrome with parathyroid, pituitary and enteropancreatic tumors. The disease phenotype segregates with markers on chromosome 11q13. Very recently a new gene was cloned from this region and was found to carry mutations in 14 of 15 unrelated MEN-1 patients. The gene was termed menin and is predicted to code for a tumor suppressor p...

متن کامل

Primary Hyperparathyroidism in Patients with Multiple Endocrine Neoplasia Type 1

Primary hyperparathyroidism may occur as a part of an inherited syndrome in a combination with pancreatic endocrine tumours and/or pituitary adenoma, which is classified as Multiple Endocrine Neoplasia type 1 (MEN-1). This syndrome is caused by a germline mutation in MEN-1 gene encoding a tumour-suppressor protein, menin. Primary hyperparathyroidism is the most frequent clinical presentation of...

متن کامل

Multiple endocrine neoplasia type 1

Combined clinical and laboratory investigations of MEN-1 have resulted in an increased understanding of this disorder, which may be inherited as an autosomal dominant condition. Defining the features of each disease manifestation in MEN-1 has improved patient management and treatment and has facilitated a screening protocol. Application of the techniques of molecular biology has enabled the ide...

متن کامل

Multiple endocrine neoplasia type 1.

Multiple endocrine neoplasia-1 (MEN-1) is an autosomal dominant inherited syndrome that occurs due to inactivating mutations of the MEN1 gene locus, coding for a tumor-suppressor protein, menin. The components of MEN-1 are hyperparathyroidism due to multiple parathyroid adenomas, pancreatic neuroendocrine tumors, and pituitary adenomas, in addition to some less common neoplastic manifestations....

متن کامل

Atypical clinical manifestations of multiple endocrine neoplasia type 1 syndrome.

Multiple endocrine neoplasia type 1 (MEN1) is a hereditary tumor syndrome characterized by a genetic predisposition to develop a variety of neuroendocrine tumors and hormone excess syndromes. The major components of MEN1 are hyperparathyroidism due to multiple parathyroid adenomas or hyperplasia, duodenopancreatic neuroendocrine tumors and pituitary adenomas, most often producing prolactin. Phy...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: Surgery

سال: 2021

ISSN: ['0039-6060', '1532-7361']

DOI: https://doi.org/10.1016/j.surg.2020.08.021